Skip to main content
Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology 2/2024

21.10.2023 | Retinal Disorders

Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up)

verfasst von: Alaa Din Abdin, Omar Hanifa, Wissam Aljundi, Cristian Munteanu, Berthold Seitz, Shady Suffo

Erschienen in: Graefe's Archive for Clinical and Experimental Ophthalmology | Ausgabe 2/2024

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate the long-term choroidal thickness changes in combination with other morphological and functional outcomes during anti-vascular endothelial growth factor (VEGF) treatment for neovascular age-related macular degeneration (nAMD) based on the subtype of macular neovascularization (MNV): MNV-1 (within the subretinal pigment epithelium space) and MNV-2 (within the subretinal space).

Methods

This retrospective study included 58 eyes from 53 patients with naïve nAMD who received anti-VEGF therapy over a 60-month period. All eyes were treated initially with intravitreal bevacizumab following Pro re nata regimen. Main outcome measures included the following: subfoveal choroidal thickness (SFCT), best corrected visual acuity (BCVA), central macular thickness (CMT), development of subfoveal geographic atrophy (GA), and the number of injections.

Results

Thirty-four eyes had MNV-1 (group 1) and 24 eyes had MNV-2 (group 2). SFCT in group 1 vs group 2 was (210 ± 45 µm vs 191 ± 52 µm, p = 0.01) before treatment and (170 ± 47 µm vs 179 ± 48 µm, p = 0.24) after 60 months. BCVA (log MAR) in group 1 vs group 2 was (0.57 ± 0.18 vs 0.53 ± 0.22, p = 0.47) before treatment and (0.59 ± 0.23 vs 0.69 ± 0.16, p = 0.04) after 60 months. CMT in group 1 vs group 2 was (398 ± 154 µm vs 382 ± 103 µm, p = 0.86) before treatment and (297 ± 68 µm vs 283 ± 67 µm, p = 0.14) after 60 months. The number of injections per eye over a period of 60 months was significantly higher in group 1 (34.9 ± 11 vs 29.0 ± 14, p = 0.04). The proportion of eyes with subfoveal GA after 60 months was significantly higher in group 2 (13 eyes, 54%) than in group 1 (9 eyes, 25%) (p = 0.03).

Conclusion

Over the full 60 months of anti-VEGF treatment, eyes with MNV-1 showed a greater reduction in choroidal thickness, better visual acuity, and less development of subfoveal geographic atrophy compared with eyes with MNV-2. The significantly thicker choroid in eyes with MNV type 1 at baseline seems to have a positive impact on long-term outcomes.
Literatur
5.
Zurück zum Zitat Gass JD (1994) Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Trans Am Ophthalmol Soc 92:91–111 (discussion 111-6)PubMedPubMedCentral Gass JD (1994) Biomicroscopic and histopathologic considerations regarding the feasibility of surgical excision of subfoveal neovascular membranes. Trans Am Ophthalmol Soc 92:91–111 (discussion 111-6)PubMedPubMedCentral
8.
Zurück zum Zitat Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5):616–636. https://doi.org/10.1016/j.ophtha.2019.11.004CrossRefPubMed Spaide RF, Jaffe GJ, Sarraf D, Freund KB, Sadda SR, Staurenghi G, Waheed NK, Chakravarthy U, Rosenfeld PJ, Holz FG, Souied EH, Cohen SY, Querques G, Ohno-Matsui K, Boyer D, Gaudric A, Blodi B, Baumal CR, Li X, Coscas GJ, Brucker A, Singerman L, Luthert P, Schmitz-Valckenberg S, Schmidt-Erfurth U, Grossniklaus HE, Wilson DJ, Guymer R, Yannuzzi LA, Chew EY, Csaky K, Monés JM, Pauleikhoff D, Tadayoni R, Fujimoto J (2020) Consensus nomenclature for reporting neovascular age-related macular degeneration data: consensus on neovascular age-related macular degeneration nomenclature study group. Ophthalmology 127(5):616–636. https://​doi.​org/​10.​1016/​j.​ophtha.​2019.​11.​004CrossRefPubMed
13.
Zurück zum Zitat Ogasawara M, Maruko I, Sugano Y, Ojima A, Sekiryu T, Iida T (2012) Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 116(7):643–649PubMed Ogasawara M, Maruko I, Sugano Y, Ojima A, Sekiryu T, Iida T (2012) Retinal and choroidal thickness changes following intravitreal ranibizumab injection for exudative age-related macular degeneration. Nippon Ganka Gakkai Zasshi 116(7):643–649PubMed
15.
Zurück zum Zitat Serra R, Coscas F, Cabral D et al (2022) Polypoidal choroidal neovascularization versus Type 1 choroidal neovascularization in age-related macular degeneration: a fractal analysis study. Retina 42(6):1005–1011CrossRefPubMedPubMedCentral Serra R, Coscas F, Cabral D et al (2022) Polypoidal choroidal neovascularization versus Type 1 choroidal neovascularization in age-related macular degeneration: a fractal analysis study. Retina 42(6):1005–1011CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, Chen CY, Marsiglia M, Boddu S, Freund KB (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 6(9):5040–5047. https://doi.org/10.1167/iovs.15-1649CrossRef Chae B, Jung JJ, Mrejen S, Gallego-Pinazo R, Yannuzzi NA, Patel SN, Chen CY, Marsiglia M, Boddu S, Freund KB (2015) Baseline predictors for good versus poor visual outcomes in the treatment of neovascular age-related macular degeneration with intravitreal anti-VEGF therapy. Invest Ophthalmol Vis Sci 6(9):5040–5047. https://​doi.​org/​10.​1167/​iovs.​15-1649CrossRef
19.
Zurück zum Zitat Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857–1867PubMedPubMedCentral Yang S, Zhao J, Sun X (2016) Resistance to anti-VEGF therapy in neovascular age-related macular degeneration: a comprehensive review. Drug Des Devel Ther 10:1857–1867PubMedPubMedCentral
20.
Zurück zum Zitat Lee CS, Kim AJ, Baughman D et al (2018) Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina 38(5):951–956CrossRefPubMedPubMedCentral Lee CS, Kim AJ, Baughman D et al (2018) Visual acuity improvement when switching from ranibizumab to aflibercept is not sustained. Retina 38(5):951–956CrossRefPubMedPubMedCentral
23.
Zurück zum Zitat Gale RP, Pearce I, Eter N et al (2020) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 104(4):493–499CrossRefPubMed Gale RP, Pearce I, Eter N et al (2020) Anatomical and functional outcomes following switching from aflibercept to ranibizumab in neovascular age-related macular degeneration in Europe: SAFARI study. Br J Ophthalmol 104(4):493–499CrossRefPubMed
38.
Zurück zum Zitat Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D (2018) Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti–vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina 38(7):1276–1288. https://doi.org/10.1097/IAE.0000000000001766CrossRefPubMed Christenbury JG, Phasukkijwatana N, Gilani F, Freund KB, Sadda S, Sarraf D (2018) Progression of macular atrophy in eyes with type 1 neovascularization and age-related macular degeneration receiving long-term intravitreal anti–vascular endothelial growth factor therapy: an optical coherence tomographic angiography analysis. Retina 38(7):1276–1288. https://​doi.​org/​10.​1097/​IAE.​0000000000001766​CrossRefPubMed
Metadaten
Titel
Long-term choroidal thickness changes based on the subtype of macular neovascularization in neovascular age-related macular degeneration (5-year follow-up)
verfasst von
Alaa Din Abdin
Omar Hanifa
Wissam Aljundi
Cristian Munteanu
Berthold Seitz
Shady Suffo
Publikationsdatum
21.10.2023
Verlag
Springer Berlin Heidelberg
Erschienen in
Graefe's Archive for Clinical and Experimental Ophthalmology / Ausgabe 2/2024
Print ISSN: 0721-832X
Elektronische ISSN: 1435-702X
DOI
https://doi.org/10.1007/s00417-023-06278-9

Weitere Artikel der Ausgabe 2/2024

Graefe's Archive for Clinical and Experimental Ophthalmology 2/2024 Zur Ausgabe

Neu im Fachgebiet Augenheilkunde

Metastase in der periokulären Region

Metastasen Leitthema

Orbitale und periokuläre metastatische Tumoren galten früher als sehr selten. Aber mit der ständigen Aktualisierung von Medikamenten und Nachweismethoden für die Krebsbehandlung werden neue Chemotherapien und Strahlenbehandlungen eingesetzt. Die …

Staging und Systemtherapie bei okulären und periokulären Metastasen

Metastasen Leitthema

Metastasen bösartiger Erkrankungen sind die häufigsten Tumoren, die im Auge diagnostiziert werden. Sie treten bei ungefähr 5–10 % der Patienten mit soliden Tumoren im Verlauf der Erkrankung auf. Besonders häufig sind diese beim Mammakarzinom und …

Wundheilung nach Trabekulektomie

Trabekulektomie CME-Artikel

Die überschießende Wundheilung in der filtrierenden Glaukomchirurgie ist ein zentraler Faktor für ein operatives Versagen. Nach der Einführung der Trabekulektomie in den 1960er-Jahren wurden viele Faktoren erkannt, die mit einer vermehrten …

„standard operating procedures“ (SOP) – Vorschlag zum therapeutischen Management bei periokulären sowie intraokulären Metastasen

Metastasen Leitthema

Peri- sowie intraokuläre Metastasen sind insgesamt gesehen selten und meist Zeichen einer fortgeschrittenen primären Tumorerkrankung. Die Therapie ist daher zumeist palliativ und selten kurativ. Zudem ist die Therapiefindung sehr individuell. Die …

Update Augenheilkunde

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.